According to Dr. Teiji Kimura, Eisai Neurology Business Group’s VP & Chief Discovery Officer, synucleinopathies have important unmet medical needs as there aren’t any powerful disease-modifying treatments. A crucial hallmark of these diseases is that the α-synuclein oligomers accumulation with protein misfolding. The group at Wren, which is made up of world-known heritage scientists, has been initiating a fundamentally different and fresh approach to address the unmet needs of their protein misfolding diseases. The recent collaboration can be expected to present substantial opportunities in identifying disease-modifying therapeutics for several patients with Parkinson’s disease, dementia with Lewy bodies, and other related ailments.
Eisai & Wren enter deal to discover treatment for synucleinopathies Wren Therapeutics has developed a distinctive kinetics drug discovery platform. This can precisely measure the impacts of small molecules on protein misfolding & aggregation pathway that leads to neurodegenerative diseases. The organization is focusing on identifying small molecules that can properly control the α-synuclein aggregation procedure, which is associated with the development and progression of these diseases. The current collaboration deal will adopt the network kinetics drug discovery platform of Wren, and Eisai’s comprehensive knowledge in drug discovery for neurodegenerative disorders to induce the progression of clinical applicants.
This exclusive arrangement is targeted towards the advancement from the novel small molecules discovery, which target α-synuclein, to treat synucleinopathies such as dementia with Lewy bodies and Parkinson’s disease.
As per the statement made by the CEO of Wren, Dr. Samuel Cohen, the biopharmaceutical firm is delighted to collaborate with Eisai. It has maintained a distinguished history and dedication to supplying innovative treatments for patients with neurodegenerative diseases. Through the combination of its unique, predictive, & quantitatively-driven platform with all the deep expertise in neurology of Eisai, both firms can collectively advance the highly differentiated small molecules that target α-synuclein to treat debilitating protein misfolding disorders like Parkinson’s disease.
Source credit: Businesswire